Many years ago when I first got into diabetes care there was constant pushback on the idea of a pharmacist managing diabetes patients. The idea that a pharmacist could actually do pump trainings was unheard of. I thought we Pharmacists would be a natural choice because of our drug knowledge, …

As we know, the holidays are very tough for many of our patients who have diabetes and/or obesity. They may have made some changes -- big changes -- in their eating habits, only to get in trouble over the long holiday season, then have a very difficult time getting back on track. The long holiday season can be a disaster to their health. I have found that for most, having leftovers at home wreaks havoc.

Tony Galliani is the National Sales Director at Companion Medical located in San Diego. With over 18 years of experience, Tony was previously Sales Director of the eastern U.S. at Tandem Diabetes Care. He also held positions at Minimed and Animas, a Johnson & Johnson company.

In this week's Homerun Slides, we begin a new category in Dr. Claude Lardinois' Endocrinology Jeopardy! This week's clue: 1.5 cm mass found on CT Scan 1 mg overnight DST cortisol is 3.3 mg/dL.

Renal cysts and diabetes (RCAD) syndrome: HNF1B-MODY
Molecular genetics of RCAD
HNF1B is a transcription factor with a role in regulating gene expression in a number of tissues. HNF1B forms homo and heterodimers with HNF1A, is present in similar tissues although at different levels, and binds to the same DNA consensus sequence. Despite these similarities HNF1B mutations cause diabetes by a different mechanism and have a distinct phenotype. There is autosomal dominant inheritance, although up to 50% of cases arise from de novo mutations or deletions.

In this Exclusive Interview, Tony Galliani talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston about InPen, a new smart pen for people who are using insulin to manage their diabetes.

In this Exclusive Interview, Tony Galliani talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston about a new smart pen for people who are using insulin to manage their diabetes.

In part 1 of this Exclusive Interview, Tony Galliani shares an overview of a new smart insulin delivery device in a conversation with Diabetes in Control Publisher Steve Freed.

In part 2 of this Exclusive Interview, Tony Galliani talks with Diabetes in Control Publisher Steve Freed about their target market, patients who are not using insulin pumps.

In part 3 of this Exclusive Interview, Tony Galliani talks with Diabetes in Control Publisher Steve Freed about the features of the new smart pen and how it compares to pumps.